Diabetes Treatment Market Size, Share & Growth Report | 2031

Segments - Diabetes Treatment Market by Product (Injectable Diabetes Drugs, Oral Drugs, Insulin Therapies, Insulin Pumps, Insulin Injection Devices, and Blood Glucose Monitoring Systems), Type (Insulin, Oral Hypoglycemic Drugs, Non-Insulin Injectable Drugs, and Others), End-user (Hospital, Personal Use, and Clinic), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023–2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

The global diabetes treatment market size was valued at about USD 30 bn in 2022 and is anticipated to reach USD 55 bn by 2031, expanding at a CAGR of 5% during the forecast period, 2022–2031. Introduction of new analytical technologies and developments of diabetes treatments are expected to fuel the market.

The body breaks down the food that is consumed into sugar or glucose, which is released into the bloodstream. When the blood sugar rises, it signals the pancreas to release insulin, which allows the sugar in the bloodstream to enter the body’s cells to use as energy.

Diabetes is a health condition in which the body is unable to utilize the glucose produced in the body. When enough insulin is not produced by the body, the cells in the body stop responding to it, thus a lot of the blood sugar stays in the bloodstream. This, overtime, causes health issues, such as heart disease, vision loss, and kidney disease.

According to The Centers for Disease Control and Prevention (CDC), the three main types of diabetes are type 1, type 2, and gestational diabetes. Type 1 diabetes is an autoimmune reaction, which prevents the body from producing insulin. It develops quickly, and is usually diagnosed among children, teenagers, and young adults.

In type 2 diabetes, the body does not use the insulin. This form of diabetes occurs over time and is diagnosed among people of varying ages. Its symptoms include weight loss, frequent urination, increased thirst and hunger, fatigue, high susceptibility to infections, slow healing of wounds, and blurry vision.

Gestational diabetes occurs among pregnant women, and can be temporary. If left untreated, it can cause health problem in the baby. This form of diabetes often goes after the baby is born. However, it increases the chances of the mother developing type 2 diabetes later in life and the child being obese while growing up.

Diabetes care treatment is necessary to enhance the treatment procedure of blood glucose monitoring system. Additionally, diabetes treatment helps enhance the quality of the patient’s life, by controlling the ailment. Diabetes drugs are medicines used for the treatment of type one and type two by reducing the blood glucose level in the body.

Blood glucose is managed by drugs such as Januvia and Byetta, monitoring diet, weight loss, and tracking fitness. Substantial improvements in the blood glucose monitoring systems to provide the critical insulin therapy with the help of insulin pumps and make them reduce painful, more accurate, and easy to use. Several types of drugs involved in the diabetes treatment, which are consumed either orally route or intravenous or subcutaneous routes.

The COVID-19 pandemic moderately impacted on the market. The pace of the market’s growth decreased, due to delays in the treatment of diabetes, as many hospitals were converted into COVID-19 centers. However, to avoid unnecessary visits to hospitals, the demand for diabetes treatment and care increased among patients, which fueled the market to a certain limit.

Diabetes Treatment Market Dynamics

Major Drivers

Urbanization, sedentary lifestyles, and obesity around the global are increasing incidences of diabetes. A large number of people lead a fast-paced and a stressful lifestyle, which increases the consumption of unhealthy food habits and alcohol. However, improving standard of living and rising awareness among people about the need for timely treatment are boosting the adoption of diabetes treatments, thereby driving the market.

Growing number of awareness programs by private companies and government organizations is raising awareness about type one and type two diabetes and their treatment, which in turn is projected to propel the market in the coming years. They are also reducing the price of treatments and drugs for diabetes treatment, thus propelling the market.

Existing Restraints

A large number of people believe in alternative medication and treatment thus, they are increasingly adopting combinational drug treatments. This, in turn, is likely to hinder the market during the forecast period.

Lack of awareness about the novel treatments and their high cost are likely to discourage the elderly and the economically backward population from adopting these treatments, thereby hampering the market.

Emerging Opportunities

Invests in the development of treatments, technology, and commercialization of diabetes treatments by companies are likely to create opportunities in the market during the forecast period.

Scope of the Diabetes Treatment Market Report

The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Diabetes Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Product (Injectable Diabetes Drugs, Oral Drugs, Insulin Therapies, Insulin Pumps, Insulin Injection Devices, and Blood Glucose Monitoring Systems), Type (Insulin, Oral Hypoglycemic Drugs, Non-Insulin Injectable Drugs, and Others), End-user (Hospital, Personal Use, and Clinic)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
Key Players Covered in the Report	Abbott Laboratories.; Amylin Pharmaceuticals Inc.; Bayer Healthcare AG; Home Diagnostics Inc.; Johnson & Johnson; Medtronic Inc.; Merck & Company Inc.; Novo Nordisk AS; and Teva Pharmaceuticals Pvt Ltd.

Market Segment Insights

On the basis of product, the market is categorized as injectable diabetes drugs, oral drugs, insulin therapies, insulin pumps, insulin injection devices, and blood glucose monitoring systems. The oral drug segment is projected to account for a considerable share of the market during the forecast period. Moreover, oral drugs consumption is preferred by most of the diabetic patients, as its administration is less painful than injections.

In terms of type, the diabetes treatment market is divided into insulin, oral hypoglycemic drugs, non-insulin injectable drugs, and others. The insulin segment is expected to constitute a significant share of the market during the forecast period. Moreover, increasing incidences of type 1 diabetes and rising number of type 2 diabetes patients relying on insulin are estimated to fuel the segment.

Around 10% of the total diabetes population rely on insulin to manage their high insulin levels. Growing awareness about the benefits of insulin among diabetes patients in emerging economies is driving the insulin segment. Additionally, rapid development in insulin delivery systems, drug and analog development by key companies and growing geriatric population are projected to fuel the segment. According to the International Diabetes Federation states, patients spent USD 760 Billion in 2019, and a large amount of it was spent by Type-1 diabetes patients on insulin drugs.

Based on end-use, the market is classified as hospital, personal use, and clinic. The hospital segment is expected to account for a large share of the market during the forecast period. A large number of patients prefer hospitals for initial diagnostic and treatment of diabetes as pharmacies, medical specialties, and diagnostic centers are easily available under one roof.

In terms of region, the global diabetes treatment market is fragmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to hold a considerable share of the market during the forecast period due to growing investments by various organizations in R&D activities. Additionally, increasing prevalence of diabetes in this region is expected to drive the market in the region. Growing awareness among consumers regarding the novel anti-diabetic drugs, new launch of anti-diabetic drugs, and presence of favorable reimbursement policies are expected to boost the market in the region.

Segments

The global diabetes treatment market has been segmented on the basis of

Products

Injectable Diabetes Drugs
Oral Drugs
Insulin Therapies
Insulin Pumps
Insulin Injection Devices
Blood Glucose Monitoring Systems

Types

Insulin
Oral Hypoglycemic Drugs
Non-Insulin Injectable Drugs
Others

End Users

Hospital
Personal Use
Clinic

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Abbott Laboratories
Amylin Pharmaceuticals Inc.
Bayer Healthcare AG
Home Diagnostics Inc.
Johnson & Johnson
Medtronic Inc.
Merck & Company Inc.
Novo Nordisk AS
Teva Pharmaceuticals Pvt Ltd.

Competitive Landscape

Major players in the global diabetes treatment market include Abbott Laboratories.; Amylin Pharmaceuticals Inc.; Bayer Healthcare AG; Home Diagnostics Inc.; Johnson & Johnson; Medtronic Inc.; Merck & Company Inc.; Novo Nordisk AS; and Teva Pharmaceuticals Pvt Ltd. These players engage in R&D investment, product development and launches, partnerships, collaborations, divestitures, geographical penetration, and mergers & acquisitions to increase their global presence and gain an edge over their competitors.

These players are focusing on the development of medication to treat stroke, kidney disease, heart disease, and obesity. They are engaged in research to develop treatment for type one and type two diabetes. A large number of emerging diabetes drugs are awaiting trial and patients are under clinical observation. These drugs are expected to enter the market during the forecast period.

In May 2022, the US Food and Drug Administration (FDA) approved the US-based pharmaceutical company, Eli Lilly’s, Mounjaro (tirzepatide) injection. It is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) used to control blood sugar in adults with type 2 diabetes.

Global Diabetes Treatment Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Diabetes Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Diabetes Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Diabetes Treatment Market - Supply Chain
  4.5. Global Diabetes Treatment Market Forecast
     4.5.1. Diabetes Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Diabetes Treatment Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Diabetes Treatment Market Absolute $ Opportunity
5. Global Diabetes Treatment Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Diabetes Treatment Market Size and Volume Forecast by Types
     5.3.1. Insulin
     5.3.2. Oral Hypoglycemic Drugs
     5.3.3. Non-Insulin Injectable Drugs
     5.3.4. Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Diabetes Treatment Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Diabetes Treatment Market Size and Volume Forecast by End Users
     6.3.1. Hospital
     6.3.2. Personal Use
     6.3.3. Clinic
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Diabetes Treatment Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Diabetes Treatment Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Diabetes Treatment Demand Share Forecast, 2019-2026
8. North America Diabetes Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Diabetes Treatment Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Diabetes Treatment Market Size and Volume Forecast by Types
     8.4.1. Insulin
     8.4.2. Oral Hypoglycemic Drugs
     8.4.3. Non-Insulin Injectable Drugs
     8.4.4. Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Diabetes Treatment Market Size and Volume Forecast by End Users
     8.7.1. Hospital
     8.7.2. Personal Use
     8.7.3. Clinic
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Diabetes Treatment Demand Share Forecast, 2019-2026
9. Latin America Diabetes Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Diabetes Treatment Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Diabetes Treatment Market Size and Volume Forecast by Types
     9.4.1. Insulin
     9.4.2. Oral Hypoglycemic Drugs
     9.4.3. Non-Insulin Injectable Drugs
     9.4.4. Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Diabetes Treatment Market Size and Volume Forecast by End Users
     9.7.1. Hospital
     9.7.2. Personal Use
     9.7.3. Clinic
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Diabetes Treatment Demand Share Forecast, 2019-2026
10. Europe Diabetes Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Diabetes Treatment Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Diabetes Treatment Market Size and Volume Forecast by Types
     10.4.1. Insulin
     10.4.2. Oral Hypoglycemic Drugs
     10.4.3. Non-Insulin Injectable Drugs
     10.4.4. Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Diabetes Treatment Market Size and Volume Forecast by End Users
     10.7.1. Hospital
     10.7.2. Personal Use
     10.7.3. Clinic
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Diabetes Treatment Demand Share Forecast, 2019-2026
11. Asia Pacific Diabetes Treatment Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Diabetes Treatment Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Diabetes Treatment Market Size and Volume Forecast by Types
     11.4.1. Insulin
     11.4.2. Oral Hypoglycemic Drugs
     11.4.3. Non-Insulin Injectable Drugs
     11.4.4. Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Diabetes Treatment Market Size and Volume Forecast by End Users
     11.7.1. Hospital
     11.7.2. Personal Use
     11.7.3. Clinic
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Diabetes Treatment Demand Share Forecast, 2019-2026
12. Middle East & Africa Diabetes Treatment Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Diabetes Treatment Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Diabetes Treatment Market Size and Volume Forecast by Types
     12.4.1. Insulin
     12.4.2. Oral Hypoglycemic Drugs
     12.4.3. Non-Insulin Injectable Drugs
     12.4.4. Others
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Diabetes Treatment Market Size and Volume Forecast by End Users
     12.7.1. Hospital
     12.7.2. Personal Use
     12.7.3. Clinic
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Diabetes Treatment Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Diabetes Treatment Market: Market Share Analysis
  13.2. Diabetes Treatment Distributors and Customers
  13.3. Diabetes Treatment Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Teva Pharmaceuticals Pvt Ltd.
     13.4.2. Novo Nordisk AS
     13.4.3. Merck & Company Inc.
     13.4.4. Medtronic Inc.
     13.4.5. Johnson & Johnson
     13.4.6. Home Diagnostics Inc.
     13.4.7. Bayer Healthcare AG
     13.4.8. Amylin Pharmaceuticals Inc.
     13.4.9. Abbott Laboratories